Open AccessA Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy
Author(s) -
Jeffrey M. Jacobson,
Hongying Wang,
Rebeka Bordi,
Zheng Li,
Barry H. Gross,
Alan Landay,
John Spritzler,
Jean Pierre Routy,
Constance A. Benson,
Judith A. Aberg,
Pablo Tebas,
David W. Haas,
Jennifer Tiu,
Kristine Coughlin,
Lynette Purdue,
Rafick Pierre Sékaly
Publication year - 2014
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000000195
Subject(s) - medicine , placebo , lymphocyte , gastroenterology , immunology , randomized controlled trial , transplantation , pathology , alternative medicine
Poor CD4 lymphocyte recovery on antiretroviral therapy (ART) is associated with reduced function of the thymus. Palifermin (keratinocyte growth factor), by providing support to the thymic epithelium, promotes lymphopoiesis in animal models of bone marrow transplantation and graft-versus-host disease.